Utility of a Simplified Lidocaine and Potassium Infusion in Diagnosing Long QT Syndrome among Patients with Borderline QTc Interval Prolongation

Annals of Noninvasive Electrocardiology

Volumn 9, Issue 1, 2004, Pages 12-18

  Chauhan, Vijay S ^a   Krahn, Andrew D ^a,b   Klein, George J ^a   Skanes, Allan C ^a   Yee, Raymond ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Antiarrhythmic agents; Arrhythmia, electrophysiology; Potassium

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIARRHYTHMIC AGENT; LIDOCAINE; POTASSIUM CHANNEL; POTASSIUM CHLORIDE; SODIUM CHANNEL; SPIRONOLACTONE;

ACCURACY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INTERMETHOD COMPARISON; LABORATORY TEST; LONG QT SYNDROME; MALE; PHENOTYPE; PRIORITY JOURNAL; QT DISPERSION; QT INTERVAL; QT PROLONGATION; REPOLARIZATION;

ADULT; CASE-CONTROL STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIDOCAINE; LONG QT SYNDROME; MALE; POTASSIUM; STATISTICS, NONPARAMETRIC;

EID: 1242270528     PISSN: 1082720X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2004.91520.x     Document Type: Article

References (31)

1. Schwartz PJ, Periti M, Malliani A. The long QT syndrome. Am Heart J 1975;89:378-390.
2. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQTI mutations cause cardiac arrhythmias. Nat Genet 1996;12:17-23.
3. Kr potassium channel. Cell 1995;81:299-307.
4. Bennett PW, Yazawa K, Makita N, et al. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995;376:683-685.
5. + channel-linked long QT syndrome. Circ Res 1996;78:916-924.
6. Priori SG, Napolitano C, Diehl L, et al. Dispersion of the QT interval: A marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation 1994;89:1681-1689.
7. Moss AJ, Zareba W, Benhorin J, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995;92:2929-2934.
8. Dausse E, Berthet M, Denjoy I. A mutation in HERG associated with notched T waves in long QT syndrome. J Mol Cell Cardiol 1996;28:1609-1615.
9. Zhang L, Timothy KW, Vincent M, et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation 2000;102:2849-2855.
10. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome: Prospective longitudinal study of 328 families. Circulation 1991;84:1136-1144.
11. An RH, Bangalore R, Roxero SZ, et al. Lidocaine block of LQT-3 mutant human Na channels. Circ Res 1996;79:103-108.
12. Wang DW, Yazawa K, Makita N, et al. Pharmacological targeting of long QT mutant sodium channels. J Clin Invest 1997;99:1714-1720.
13. + channels. Am J Physiol 1998;274:H477-H487.
14. Kambouris NG, Nuss HB, Johns DC, et al. A revised view of cardiac sodium channel "blockade" in the long-QT syndrome. J Clin Invest 2000;105:1133-1140.
15. Priori SG, Napolitano C, Cantu F, et al. Differential response to Na channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long QT syndrome. Circ Res 1996;78:1009-1015.
16. Shimizu W, Antzelevitch C. Sodium channel block with mexilitine is effective in reducing dispersion of repolarization and preventing torsade do pointes in LQT2 and LQT3 models of the long QT syndrome. Circulation 1997;96:2038-2047.
17. Sicouri S, Antzelevitch D, Heilmann C, et al. Effects of sodium channel block with mexilitine to reverse action potential prolongation in in vitro models of the long QT syndrome. J Cardiovasc Electrophysiol 1997;8:1280-1290.
18. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na channel blockade and to increases in heart rate: Implications for gene-specific therapy. Circulation 1995;92:3381-3386.
19. + currents. Pflugers Arch 1992;420:180-186.
20. Kr: Implications for torsade de pointes and reverse use-dependence. Circulation 1996;93:407-411.
21. Compton SJ, Lux RL, Ramsey MR, et al. Genetically defined therapy of inherited long-QT syndrome: Correction of abnormal repolarization by potassium. Circulation 1996;94:1018-1022.
22. Tan HL, Alings M, Van Olden RW, et al. Long-term (subacute) potassium treatment in congenital HERG-related long QT syndrome. J Cardiovasc Electrophysiol 1999;10:229-233.
23. McAllister RE, Noble D. The time and voltage dependence of the slow outward current in cardiac Purkinje fibres. J Physiol 1966;186:632-662.
24. Dudel J, Peper K, Rudel R, et al. The potassium component of membrane current in Purkinje fibers. Pflugers Arch 1967;296:308-327.
25. Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome: An update. Circulation 1993;88:782-784.
26. Lepeschkin E, Surawicz B. The measurement of the QT interval of the electrocardiogram. Circulation 1952;VI:378-388.
27. Bazett HC. An analysis of time relations of electrocardiograms. Heart 1920;7:353-370.
28. Benhorin J, Taub R, Goldmit M, et al. Effects of flecainide in patients with new SCN5A mutation: Mutation-specific therapy for long QT syndrome? Circulation 2000;101:1698-1706.
29. Shimizu W, Kurita T, Matsuo K, et al. Improvement of repolarization abnormalities by a K channel opener in the LQT1 form of congenital long QT syndrome. Circulation 1998;97:1581-1588.
30. + channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation 2000;102:706-712.
31. Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997;96:2149-2154.